<DOC>
	<DOCNO>NCT00030472</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness liposomal doxorubicin treat patient persistent recurrent cancer cervix .</brief_summary>
	<brief_title>Liposomal Doxorubicin Treating Patients With Persistent Recurrent Cancer Cervix</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity doxorubicin HCl liposome patient persistent recurrent squamous cell carcinoma cervix . - Determine toxicity drug patient . OUTLINE : This multicenter study . Patients receive doxorubicin HCl liposome IV 1 hour day 1 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 22-60 patient accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma ( SCC ) cervix Persistent recurrent progressive disease Must fail local therapeutic measure consider incurable 1 prior chemotherapeutic regimen SCC cervix require Initial treatment may include highdose therapy , consolidation , extend therapy Ineligible high priority GOG protocol At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR At least 10 mm spiral CT scan Target lesion may within previously irradiate field PATIENT CHARACTERISTICS : Age : Any age Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm3 Absolute neutrophil count least 1,500/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT great 2.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No congestive heart failure No unstable angina No myocardial infarction new cardiac arrhythmia past 6 month Other : No active infection require antibiotic No invasive malignancy within past 5 year except nonmelanoma skin cancer Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : 1 prior noncytotoxic biologic regimen ( e.g. , monoclonal antibody , cytokine , smallmolecule inhibitor signal transduction ) allow recurrent persistent disease ( provided patient receive noncytotoxic cytostatic regimen recurrent persistent disease management ) At least 3 week since prior biologic immunologic therapy SCC cervix Chemotherapy : See Disease Characteristics No prior doxorubicin doxorubicin HCl liposome 1 prior noncytotoxic cytostatic regimen allow recurrent persistent disease ( provided patient receive noncytotoxic biologic regimen recurrent persistent disease management ) No prior cytotoxic chemotherapy recurrent persistent disease , include retreatment initial chemotherapy regimen Recovered prior chemotherapy Endocrine therapy : At least 1 week since prior hormonal therapy SCC cervix Concurrent hormone replacement therapy allow Radiotherapy : See Disease Characteristics Recovered prior radiotherapy Surgery : Recovered prior surgery Other : At least 3 week since prior therapy SCC cervix No prior anticancer treatment precludes study</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2004</verification_date>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
</DOC>